Nucleotide degrading enzymes in platelets from uterine cervical neoplasia patients treated with conization or radiotherapy

Biomedicine and Pharmacotherapy

Volumn 64, Issue 7, 2010, Pages 499-504

  Maldonado, Paula Acosta ^a   Negrini, Luiz Augusto ^a   Ethur, João da Silva ^a   Oliveira, Liliane ^a   Corrêa, Maísa de Carvalho ^a   Becker, Lara Vargas ^a   Zanin, Rafael Fernandes ^a   Morsch, Vera Maria ^a   Schetinger, Maria Rosa Chitolina ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Ectonucleotidases; Platelets; Uterine cervical neoplasia

Indexed keywords

5' NUCLEOTIDASE; ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; NUCLEOSIDE TRIPHOSPHATE; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION;

5'-NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADULT; ANTIGENS, CD; APYRASE; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CONIZATION; FEMALE; HUMANS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET COUNT; PLATELET-RICH PLASMA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77956425371     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.02.007     Document Type: Article

References (40)

1. Olas B., Wachowicz B., Mielicki W.P. Cancer procoagulant and blood platelet activation. Cancer Lett 2001, 169:165-171.
2. Lin J., Proctor M.C., Varma M., Greenfield L.J., Upchurch G.R., Henke P.K. Factors associated with recurrent thromboembolism in patients with malignant disease. J Vasc Surg 2003, 37(5):976-983.
3. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004, 50(3):187-196.
4. Bick R.L. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992, 18(4):353-372.
5. Hernandez E., Donohue M.A., Anderson L.L., Heller P.B., Stehman F.B. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: A gynecologic oncology group study. Gynecol Oncol 2000, 78(2):137-142.
6. Karpatkin S., Pearlstein E. Role of platelets in tumor cell metastases. Annals Int Med 1981, 95(5):636-641.
7. Cervical cancer [http://www.medlineplus.gov].
8. Janicek M.F., Averette H.E. Cervical cancer: prevention, diagnosis and therapeutics. CA Cancer J Clin 2006, 51(2):92-114.
9. Bennett J.C., Cecil P.F. Tratado de Medicina Interna. Guanabara Koogan 1997.
10. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn W., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367(9509):489-498.
11. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005, 6(6):401-410.
12. Barbera L., Thomas G. Venous thromboembolism in cervical cancer. Lancet Oncol 2008, 954-960.
13. Tateo S., Mereu L., Salamano S., Klersy C., Barone M., Spyropoulos A.C., et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005, 99(1):119-125.
14. Jacobson G., Lammli G., Zamba G., Hua L., Goodheart M.J. Thromboembolic events in patients with cervical carcinoma: incidence and effect on survival. Gynecol Oncol 2009, 113:240-244.
15. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., Islam N., Pinsky D.J., Sesti C., et al. Metabollic control of excessive extracellular nucleotide accumulation by CD39/ecto nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 2003, 305(1):9-16.
16. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., Islam N., Pinsky D.J., Sesti C., et al. Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 2001, 21(2):178-182.
17. Enjyoji K., Lin Y., Frenete P.S., Christie P.D., Am Esch J.S., Imai M., et al. Target disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999, 5(9):1010-1017.
18. Bakker W.W., Poelstra K., Barradas M.A., Mikhailidis D.P. Platelets and ectonucleotidases. Platelets 1994, 5:121-129.
19. Robson S.C., Sévigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006, 2:409-430.
20. Dubyak G. Focus on extracellular ATP signaling and P2X nucleotide receptors in monolayers of primary human vascular endothelial cells. Am J Physio Cell Physiol 2002, 282(2):242-244.
21. Atkinson B., Dwyer K., Enjyoji K., Robson S.C. Ectonucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cell Mol Dis 2006, 36(2):217-222.
22. Schetinger M.R.C., Morsch V.M., Bonan C.D., Wyse A.T.S. NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. Biofactors 2007, 31(2):77-98.
23. Qawi I., Robson S.C. New developments in anti-platelet therapies: potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders. Curr Drug Targets 2000, 1285-1296.
24. Spychala J. Tumor promoting functions of adenosine. Pharmacol Ther 2000, 87(2-3):161-173.
25. Lunkes G.I., Lunkes D., Stefanello F., Morsch A., Morsch V.M., Mazzanti C.M., et al. Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies. Thromb Res 2003, 109(4):189-194.
26. Araújo M.C., Rocha J.B.T., Morsch A., Zanin R., Bauchspiess R., Morsch V.M., et al. Enzymes that hydrolyze adenine nucleotides in platelets from breast cancer patients. Biochim Biophys Acta 2005, 1740(3):421-426.
27. Pilla C., Emanuelli T., Frassetto S.S., Battastini A.M.O., Dias R.D., Sarkis J.J.F. ATP diphosphohydrolase activity (Apyrase EC 3.6.1.5.) in human blood platelets. Platelets 1996, 7:225-230.
28. 2+-ATPase activity. Anal Biochem 1986, 157:375-380.
29. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:218-254.
30. Benedet J.L., Hacker N.F., Ngam H.Y.S. FIGO: International Federation of Gynecology and Obstetrics. Staging Classif Clin Pract Guidel Gynaecol cancers 2003, 1-160.
31. Kasamatsu T., Okada S., Tsuda H., Shiromizu K., Yamada T., Tsunematsu R., et al. Early invasive adenocarcinoma of the uterine cervix: criteria for nonradical surgical treatment. Gynecol Oncol 2002, 85(2):327-332.
32. Fimognari F.L., Repetto L., Moro L., Gianni W., Incalzi R.A. Age, cancer and the risk of venous thromboembolism. Crit Rev Oncol Hematol 2005, 55(3):207-212.
33. Park H.S., Hourani S.M.O. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5'-diphosphate (ADP) in human platelets. Br J Pharmacol 1999, 127(6):1359-1366.
34. Prandoni P., Piccioli A., Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999, 84(5):437-445.
35. Haskó G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004, 25(1):33-39.
36. Bours M.J.L., Swennen E.L.R., Di Virgilio F., Cronstein B.N., Dagnelie P.C. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006, 112(2):358-364.
37. Hunsuckera S.A., Mitchella B.S., Spychala J. The 5'-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005, 107(1):1-30.
38. Munson L., Upadhyaya N.B., Meter S.V. Platelet-derived growth factor promotes endometrial epithelial cell proliferation. Am J Obstet Gynecol 1995, 173(6):1820-1825.
39. Hernandez E., Lavine M., Dunton C.J., Gracely E., Parker J. Poor prognostic associated with thrombocytosis in patients with cervical cancer. Cancer 1992, 69:2975-2977.
40. Rapaport SI. Hematologia - Introdução, 2a ed., Editora Roca, São Paulo, 1990. p. 426-40.